Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Julio RosenstockLawrence BlondeVanita R ArodaJuan Pablo FriasElisabeth SouhamiChen JiElisabeth NiemoellerStephano Del PratoPublished in: Diabetes, obesity & metabolism (2021)
Switching to iGlarLixi improved glycaemic control, regardless of screening HbA1c or previous GLP-1 RA type, offering a simple, efficacious and well-tolerated treatment intensification option for people with T2D inadequately controlled by GLP-1 RAs and OADs.